1nm pp1 (MedChemExpress)
Structured Review

1nm Pp1, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 9 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/1nm pp1/product/MedChemExpress
Average 92 stars, based on 9 article reviews
Images
1) Product Images from "Congress of multiple dimers is needed for cross-phosphorylation of IRE1α and its RNase activity"
Article Title: Congress of multiple dimers is needed for cross-phosphorylation of IRE1α and its RNase activity
Journal: Life Science Alliance
doi: 10.26508/lsa.202302562
Figure Legend Snippet: (A) Cells reconstituted with FL-, dim-, dim-DDD- and dim-KB-IRE1 were induced with different concentrations of doxycycline to induce comparable low, medium, and high expression levels, as indicated. IRE1 mutant proteins were revealed by immunoblot with anti-IRE1 antibodies. (B) Cells expressing dim-DDD- and dim-KB-IRE1 at low or high levels were treated with AP20187 (green) and/or 1NM-PP1 (blue) as indicated. Immunoblot analysis with anti-IRE1 antibodies shows that none of the treatments alter the expression levels of either of the two IRE1 mutants. (C) Similar to , HeLa cell lines expressing KB- and KB-DDD-IRE1α mutants under the TetON-inducible promoter were treated with different concentrations of doxycycline to adjust the expression level of the transgenes to comparable levels between each other (low and medium levels in this case). Aliquots from the cell lysates were resolved electrophoretically and the blots decorated with anti-IRE1α. (D) Microscopy images of cells expressing GFP-tagged KB- and KB-DDD-IRE1 at the medium expression level (see (C)). The boxed area in each image is shown magnified on the right, to facilitate the comparison. KB-DDD-IRE1 forms distinct foci upon treatment with Tm and 1NM-PP1, whereas KB-IRE1 does not. All images have been acquired with the same magnification; scale bar (valid for all panels) = 10 μm.
Techniques Used: Expressing, Mutagenesis, Western Blot, Microscopy, Comparison
Figure Legend Snippet: (A) Cells expressing endogenous IRE1 were treated with dimerizing drug AP20187, nucleotide analog 1NM-PP1, and/or Tm, as indicated. As shown by the XBP1 splicing assay, in none of the conditions AP20187 and/or 1NM-PP1 affected endonuclease activity of wt IRE1. (B) HeLa cells reconstituted with full-length (FL) or dimerizable (dim) IRE1 were treated with doxycycline to achieve low or high expression levels of the respective protein. Cells were then treated with Tm (red) or AP20187 (green). Neither of the treatments alter the expression levels of IRE1, as shown by immunoblot with anti-IRE1 antibodies. A similar result for two other IRE1 mutants is shown in . (C) Cells expressing dim-IRE1 at high or medium levels were treated with increasing concentrations of AP20187 as indicated. As shown by the XBP1 splicing assay, a concentration of 5 nM is already sufficient to activate endonuclease activity if dim-IRE1 is expressed at high levels. On the contrary, if dim-IRE1 is present in lesser amounts (medium expression) AP20187 is unable to trigger XBP1 splicing even at 320 nM concentration. Key for activation is therefore the concentration of IRE1 dimers. In the rest of the study, unless differently stated, we have used AP20187 at a concentration of 10 nM.
Techniques Used: Expressing, Splicing Assay, Activity Assay, Western Blot, Concentration Assay, Activation Assay
Figure Legend Snippet: (A) Endonuclease activity of dimerizable IRE1α mutants at different expression levels (low, medium, high) after treatment with or without dimerizing drug (AP20187, green) and with or without 1NM-PP1 (blue). (B) Cells expressing FL-, dim-KB-, and dim-DDD-IRE1, at low or high levels as indicated, were treated with Tm (red) or AP20187 (green). The phosphorylation state of IRE1 mutants was assessed by Phos-tag gels and immunoblot with anti-IRE1 antibodies. dim-DDD (because of the substitutions of the three serines) and dim-KB (because of the inability to bind ATP and, hence, phosphotransfer) cannot be phosphorylated even if highly expressed. (C) Endonuclease activity of nucleotide binding requiring (KB-)IRE1α mutants, expressed at low and medium levels, after treatment with Tm (red) and/or NM-PP1 (blue), as indicated. KB-DDD-IRE1α was used to evaluate the possible role of phosphorylation in stabilization of the nucleotide-bound state. XBP1 splicing by both KB mutants depends on nucleotide activation (compare, for instance, lanes 1–2 with 3–4), intracellular concentration (compare lanes 3 with 7 or 4 with 8), and phosphorylation (compare lanes 3 with 11 or 4 with 12). (D) Confocal images of cells expressing GFP-tagged dim-DDD-IRE1. Even at high expression levels the mutant does not form foci upon treatment with AP20187. Scale bar = 10 μm.
Techniques Used: Activity Assay, Expressing, Western Blot, Binding Assay, Activation Assay, Concentration Assay, Mutagenesis
